ClinicalTrials.gg
TerminatedNCT02605044Updated Feb 11, 2019

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

A Phase 3 interventional study of Masitinib (AB1010) and FOLFIRI in Metastatic Colorectal Cancer, sponsored by AB Science. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-11.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 581 studies in Colorectal Neoplasms with a site in France — 109 open to participants now, 164 under way, 26 of them phase 3. Colorectal Neoplasms · France.

Enrollment
252nd of 463
123 · median 152
Started
2014
with 21 others
Phase 3
89 of 581
12 open now
Registered
231st of 581
by date

Among the 581 studies in Colorectal Neoplasms with a site in France, this one is the 252nd largest by enrollment of the 463 interventional ones that give a count, is one of 22 that started in 2014, is one of 89 in phase 3, and was the 231st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

109 of the 581 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 581 studies in Colorectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with non-resectable colorectal cancer
  • Metastatic disease not amenable to surgical resection
  • Patient in treatment after progression according to criteria
  • Patient with according to RECIST criteria (version 1.1)
  • Patient eligible for a standard second line treatment with FOLFIRI
  • Patient with ≤ 2
  • Patient with adequate organ function
  • Patient with > 3 months
  • Female or male patient ≥ 18
  • Patient weight > 40 kg and > 18

Exclusion criteria

Exclusion Criteria:

  • Patient who cannot receive FOLFIRI
  • More than 1 prior chemotherapy regimens for colorectal cancer
  • Pregnant, intent to be pregnant, or nursing female patient
  • Patient with any chronic inflammatory bowel disease
  • Patient treated for a cancer other than colorectal cancer within five years before enrollment
  • Patient with an hepatic involvement > 50%
  • Patient with active central nervous system (CNS) metastasis or history of
  • Patient with an active infection
  • Patient presenting with cardiac disorders
  • Any previous treatment with an agent or chemotherapy or biological agent within four weeks prior to baseline.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Masitinib + FOLFIRI

    masitinib + FOLFIRI

    Drug: Masitinib (AB1010) · Drug: FOLFIRI

  • Placebo comparator
    Placebo + FOLFIRI

    Placebo + FOLFIRI

    Drug: FOLFIRI

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to death, assessed for a maximum of 60 months

Secondary outcomes

  1. Survival rate

    Survival rate is defined as the proportion of patients alive at each time point, estimated with Kaplan-Meier distribution

    Time frame: Every 24 weeks, assessed up to 60 months

  2. Progression Free Survival (PFS)

    Progression Free Survival is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by the investigator on CT scan according to RECIST 1.1 criteria

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

07

Study locations

3 sites
  • Hopital Europeen George Pomipidou, Hepato-Gastro-enterologie, 20 rue Leblanc
    Paris, 75, France
  • National Cancer Center, 11 Hospital Drive
    Singapore, 169610, Singapore
  • Hammersmith Hospital, Department of Cancer Medicine, Imperial College Healthcare Trust, Du Cane Road
    London, W12 0HS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2015
First posted
Nov 16, 2015
Start
Jan 2014
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Results delay requested
Jan 25, 2019
Last update
Feb 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02605044
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Nov 16, 2015
Start date
Jan 2014
Primary completion
Dec 2017
Completion
Dec 2017
Last update
Feb 11, 2019

Study contacts

Julien Taieb, PhD, MD
principal investigator · Hôpital Européen Georges Pompidou, Paris, France
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion